← All trials
NCT03990805
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 11, 2019
- Primary completion
- Jun 3, 2020
- Completion date
- Nov 30, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 260
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- R-BiopharmLead sponsor
- Kyung Hee UniversityOverall official - principal investigator
- Chonbuk National UniversityOverall official - principal investigator
- Yeungnam UniversityOverall official - principal investigator
- Soonchunhyang UniversityOverall official - principal investigator
- Sungkyunkwan UniversityOverall official - principal investigator
- Yonsei UniversityOverall official - principal investigator
- Keimyung UniversityOverall official - principal investigator
- Gyeongsang UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.